As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

UK-based As­traZeneca is steer­ing a sig­nif­i­cant amount of R&D and man­u­fac­tur­ing spend­ing to France,

On the Mon­day hol­i­day, the phar­ma gi­ant made a splash with its French re­lease out­lin­ing plans by CEO Pas­cal So­ri­ot — a na­tive of France — to in­vest $275 mil­lion in ad­di­tion­al R&D part­ner­ing with its grow­ing net­work of French biotech and re­search groups. In par­tic­u­lar, As­traZeneca ex­ecs want to amp up their work in­volv­ing French re­searchers in their glob­al clin­i­cal tri­al net­work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER